R heumatoid Arthritis (RA) is an autoimmune disease in which the patient’s immune system generates cellular and antibody responses to various components of the joint such as type I collagen. As a result of this immune response, not only does joint destruction occur, but also other secondary complications such as pulmonary fibrosis, renal damage, and even heart damage.
C urrently, RA is treated with immune suppressive agents such as steroids , methotrexate , cyclosporine ,gold , and more recently infliximab ( Remicade ). Despite inducing temporary improvement, these approaches possess long-term adverse effects due to non-specific inhibition of immune responses. Additionally, current treatments do not address the issue of damage that has already occurred to the joints or extra-articular tissues.
Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. Stem cell therapy has been demonstrated to induce profound healing activity in animals with various forms of arthritis. Besides healing of damaged tissues, stem cells specifically, ASP stem cellsASP stem cells have the unique ability to modulate the immune system so as to shut off pathological responses while preserving ability to fight off disease. These mediators act locally and do not suppress the immune response of the patient’s whole body.